PARP Inhibitors in Cancer Therapy: From Historical Development to Precision Oncology

Over the past decades, poly(ADP-ribose) polymerase inhibitors (PARPis) have reshaped the treatment of multiple solid tumors, including ovarian, breast, pancreatic, and prostate carcinomas, becoming the first-line maintenance therapy following chemotherapy in tumors harboring defects in the homologous recombination (HR) repair pathway, most notably through BRCA1/2 gene mutations. This review traces the development of PARPis from the seminal discovery of PARP enzymes to the clinical approval of different classes of PARPis, discussing their classification according to the mechanisms of action and isoform selectivity. We then discuss the molecular determinants of response, including BRCA1/2 mutation type and location, alterations in other HR repair genes, and functional HR deficiency biomarkers, together with HR-independent responses. Further, this review summarizes the pivotal Phase III trials supporting the use of PARPis across different tumor types and regardless of their HR status, and how clinical data has led to the restriction or withdrawal of several later-line indications, while supporting PARPi use in earlier disease stages. Lastly, we examine the mechanisms of acquired resistance and the pharmacological strategies to overcome it, including combinations with immune checkpoint inhibitors and inhibitors of the DNA damage response pathway, and the combinatorial opportunities offered by the newly developed PARP1-selective inhibitors. Overall, this review underscores the clinical impact of PARP inhibition in cancer therapy and highlights the holistic stratification of patients based on genomic and functional assays as key to maximizing the therapeutic potential of PARPi.

Authors

Institutions

Publication Details

Journal
Genes
Published
2026-11-18
DOI
https://doi.org/10.3390/genes17111458
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

PARP Inhibitors in Cancer Therapy: From Historical Development to Precision Oncology

Francesca Citron, Elisabetta Granato, Luca Cecchetto, Sergio Attanasio
2 links
Genes
PARP inhibition in cancer therapy
article

PARP Inhibitors in Cancer Therapy: From Historical Development to Precision Oncology

Francesca Citron, Elisabetta Granato, Luca Cecchetto, Sergio Attanasio
article en

Abstract

Over the past decades, poly(ADP-ribose) polymerase inhibitors (PARPis) have reshaped the treatment of multiple solid tumors, including ovarian, breast, pancreatic, and prostate carcinomas, becoming the first-line maintenance therapy following chemotherapy in tumors harboring defects in the homologous recombination (HR) repair pathway, most notably through BRCA1/2 gene mutations. This review traces the development of PARPis from the seminal discovery of PARP enzymes to the clinical approval of different classes of PARPis, discussing their classification according to the mechanisms of action and isoform selectivity. We then discuss the molecular determinants of response, including BRCA1/2 mutation type and location, alterations in other HR repair genes, and functional HR deficiency biomarkers, together with HR-independent responses. Further, this review summarizes the pivotal Phase III trials supporting the use of PARPis across different tumor types and regardless of their HR status, and how clinical data has led to the restriction or withdrawal of several later-line indications, while supporting PARPi use in earlier disease stages. Lastly, we examine the mechanisms of acquired resistance and the pharmacological strategies to overcome it, including combinations with immune checkpoint inhibitors and inhibitors of the DNA damage response pathway, and the combinatorial opportunities offered by the newly developed PARP1-selective inhibitors. Overall, this review underscores the clinical impact of PARP inhibition in cancer therapy and highlights the holistic stratification of patients based on genomic and functional assays as key to maximizing the therapeutic potential of PARPi.

GenesVol. 17(11)
The University of Texas MD Anderson Cancer Center (US)
Good health and well-being
PARP inhibition in cancer therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon